Articles

FDA's Restructuring Opportunity Amid China Competition

This article discusses the FDA's chance to restructure following recent challenges and the implications for the pharmaceutical industry amid competition from China.

Friday Five: Key Regulatory Updates in Pharma

This article covers significant regulatory updates impacting the pharmaceutical industry, including GSK's breakthrough in hepatitis B and Eli Lilly's advancements in prevention.

Zydus Lifesciences Secures FDA Priority Review for Liver Disease Drug

Zydus Lifesciences has secured a priority review from the US FDA for its liver disease drug application. This development could significantly impact the company's market positioning.

BioNTech and Pfizer's Bispecifics Data: Insights and Implications

BioNTech and Pfizer present promising bispecifics data, while FDA's Pazdur highlights potential opportunities. Discover the implications for the pharma sector.

Concerns Over GLP-1 Microdoses: A Weight-Loss Doctor's Perspective

This article explores the concerns of a weight-loss doctor regarding the rise of GLP-1 microdoses, highlighting potential risks and implications for the pharmaceutical industry.

STAT+: The Woman Behind the World’s Biggest Longevity Competition

Discover the pivotal role of Jamie Justice in the world's largest longevity competition and its implications for the pharmaceutical industry.

Philips Partners with Disney to Alleviate MRI Anxiety in Children

Philips has partnered with Disney to create a more comforting MRI experience for children. This innovative approach aims to reduce anxiety and improve patient outcomes.

Can a Chaotic FDA Still Deliver on Faster Drug Development?

This article examines the FDA's chaotic environment and its impact on drug development timelines. We analyze the implications for pharmaceutical teams navigating these changes.

Bristol Myers Unveils Next-Gen Blood Cancer Drug Data

Bristol Myers has revealed promising data for its next-generation blood cancer drug, Mezigdomide. This article explores the implications for the pharmaceutical landscape.

Which Vaccines Will Curb the Ebola Outbreak? WHO Debates

The WHO is currently debating which vaccines will effectively curb the ongoing Ebola outbreak. This article explores the implications for pharmaceutical teams and investors.

Fierce Pharma Asia: Key Insights on Recent Deals and Trends

This article provides a comprehensive overview of the latest developments in the pharmaceutical industry, focusing on Pfizer's $10B Innovent deal and Astellas' strategic roadmap.

Modernizing Patient Support in Pharma Amid Rising Young Adult Cancer Rates

As young adult cancer rates increase, pharmaceutical companies are urged to modernize their patient support systems. This article outlines key developments and implications for the industry.

Massachusetts Sues UnitedHealth Over Medicaid Fraud Allegations

Massachusetts has filed a lawsuit against UnitedHealth, alleging fraudulent practices in Medicaid plans for seniors. This article explores the implications for the pharmaceutical industry.

FDA Draft Guidance Reduces Animal Testing for Cancer Drugs

The FDA has issued a draft guidance to minimize unnecessary animal testing in cancer drug development. This change could significantly impact pharmaceutical companies and their research strategies.

Pfizer and Innovent's $10B Cancer Drug Deal: Key Insights

Pfizer and Innovent have entered a significant $10B deal focusing on cancer therapeutics. This article delves into the implications for the pharmaceutical landscape.

Allogene CEO Departure and Agios Drug Setback: What It Means for Pharma

Allogene's CEO is stepping down amid significant challenges, while Agios faces a setback with its drug failing a key test. This article explores the implications for the industry.

MannKind's Pediatric Expansion: A Game Changer for Afrezza Sales

MannKind aims to enhance sales of its inhaled insulin, Afrezza, with new FDA approval for pediatric use. This article analyzes the implications for investors and pharma teams.

Trump Administration's Overhaul of Federal Grantmaking: Impacts on Pharma

The Trump administration's proposed overhaul of the federal grantmaking process raises concerns among researchers. This article explores the potential impacts on the pharmaceutical industry.

Replimune's Third Attempt at Cancer Drug Approval: Insights from FDA Talks

Replimune is making its third attempt to gain FDA approval for its cancer drug following productive discussions. This article explores the implications for investors and pharma teams.

Zydus Therapeutics' Saroglitazar Receives FDA Priority Review

Zydus Therapeutics' saroglitazar has received priority review from the US FDA, marking a significant regulatory milestone. This analysis explores the implications for investors and pharma teams.